Viewing Study NCT05394233


Ignite Creation Date: 2025-12-25 @ 2:43 AM
Ignite Modification Date: 2025-12-27 @ 11:29 PM
Study NCT ID: NCT05394233
Status: UNKNOWN
Last Update Posted: 2022-05-27
First Post: 2022-05-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
Sponsor: Sichuan Cancer Hospital and Research Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module